- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01781884
Effects Of Gamma Aminobutyric Acid On The Progression Of New Onset Juvenile Type 1 Diabetes
Effects Of Gamma Aminobutyric Acid On The Progression Of New Onset Juvenile
This study is a multicenter, randomized, double-masked, placebo-controlled clinical study. All groups will receive standard intensive diabetes treatment with insulin and life style management. 60 subjects will be randomly assigned in a 1:1:1 ratio to receive placebo or different dosage of GABA.
GABA is an amino acid produced from glutamate by glutamic acid decarboxylase. It was approved for the treatment of hepatic coma, fibromyalgia, ataxia in China and is widely used as supplement for the treatment of epilepsy, insomnia, stress and tobacco dependence. It has been recently shown that GABA can prevent and reverse the development of diabetes in type 1 mice models. Participants will receive placebo or GABA for 52 weeks.
The study will consist of 4 weeks screening period, 2 weeks run-in period, 52 weeks treatment period and 4 weeks follow-up period. Enrollment is expected to occur over 2 years.
To assess the efficacy and safety of GABA for the treatment of juvenile type 1 diabetes in new onset subjects.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Primary Outcome:
The primary statistical hypothesis to be assessed in this study is whether the mean C-peptide value for study subjects receiving GABA differs significantly from the mean value for placebo subjects assessed at follow-up.
Secondary Outcome:
The study will examine the HbA1C and the daily dosage of insulin (units/kg).
Exploratory Endpoint:
The study will assess the effects of treatment on inflammatory markers and immunological outcomes.
Major Inclusion Criteria:
Type 1 diabetes within past 6 months Age 5-21 years* At least one diabetes associated autoantibody
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200040
- Recruiting
- Department of Endocrinology and Metabolism,Huashan hospital
-
Contact:
- Zhaoyun Zhang
- Phone Number: 86-21-52888286
-
Contact:
- Yi Wang
- Phone Number: 86-21-52887022
-
Principal Investigator:
- Yiming Li
-
Principal Investigator:
- Qinghua Wang, Doctor
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Be between the ages of 5 and 21 years*
- Be within 6-months of diagnosis of type 1 diabetes based on American Diabetes Association (ADA) criteria
- Must have stimulated C-peptide levels ≥0.2 pmol/ml measured during a mixed meal tolerance test (MMTT) conducted at least 21 days from diagnosis of diabetes and within one month of randomization
- Presence of at least one diabetes-related autoantibody
- Must be willing to comply with intensive diabetes management and monitor glucose with glucometer.
- If participant is female with reproductive potential, she must be willing to avoid pregnancy during the whole study period and have a negative pregnancy test
- Parents and participants must sign the informed consent
Exclusion Criteria:
- Be currently pregnant or lactating or anticipate getting pregnant during the study period.
- Type 2 diabetes and other specific types of diabetes.
- Require use of systemic immunosuppressant, steroids or other medications that can affect glucose metabolism.
- Have a history of malignancies
- Be currently using non-insulin pharmaceuticals to affect glycemic control
- Have any acute or chronic complicating medical issues or abnormal clinical laboratory results that interfere with study conduct or cause increased risk.
- Have a history of epilepsy, significant head trauma or cerebrovascular accident or clinical features of continuous motor unit activity in proximal muscles
- Inability or unwillingness to comply with the provisions of this protocol
- Have an active infection or positive PPD test result.
- Have serologic evidence of current or past HIV, Hep B, or Hep C infection.
- Be with acute complications of diabetes (diabetic ketoacidosis, nonketotic hypersmolar coma, diabetic lactic acidosis)
- Have a history of chronic renal failure, serum creatinine higher than 177umol/L
- Have a history of impaired liver function, ALT or AST level elevated more than (or equal to) 2.5 times of upper limmit normal.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Gamma Aminobutyric Acid (GABA)
GABA will be given 50mg/kg/Day, thrice daily for 52 weeks
|
two dosages will be used in this study.
GABA: 50mg/kg/day and 100mg/kg/day
Other Names:
|
Active Comparator: Gamma Aminobutyric Acid GABA)
GABA will be given 100mg/kg/Day, thrice daily for 52 weeks.
|
two dosages will be used in this study.
GABA: 50mg/kg/day and 100mg/kg/day
Other Names:
|
Placebo Comparator: placebo
placebo will be given thrice daily for 52 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
C-peptide value
Time Frame: baseline and up to 52 weeks
|
The primary statistical hypothesis to be assessed in this study is whether the mean C-peptide value for study subjects receiving GABA differs significantly from the mean value for placebo subjects assessed at follow-up.
|
baseline and up to 52 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
HbA1C level
Time Frame: baseline and up to 52 weeks
|
The study will examine the HbA1C level every 3 months from baseline and up to 52 weeks.
|
baseline and up to 52 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Daily dosage of insulin (units/kg).
Time Frame: baseline and up to 52 weeks
|
The study will assess the daily dosage of insulin (units/kg).
|
baseline and up to 52 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Yiming Li, Doctor, Huashan Hospital
- Principal Investigator: Qinghua Wang, Doctor, St Michale's Hospital, University of Toronto
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2012-024
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 1 Diabetes
-
Poznan University of Medical SciencesUnknownDiabetes Mellitus Type 1 | Remission of Type 1 Diabetes | Chronic Complications of DiabetesPoland
-
Eledon PharmaceuticalsWithdrawnBrittle Type 1 Diabetes MellitusUnited States
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)CompletedType 1 Diabetes Mellitus | T1DM | T1D | New-onset Type 1 Diabetes MellitusUnited States, Australia
-
Hoffmann-La RocheCompletedType 2 Diabetes, Type 1 DiabetesAustria, United Kingdom
-
Shanghai Changzheng HospitalRecruitingBrittle Type 1 Diabetes MellitusChina
-
Capillary Biomedical, Inc.TerminatedType 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMAustria
-
Capillary Biomedical, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Insulin-Dependent, 1Australia
-
AstraZenecaCompletedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
NYU Langone HealthNational Heart, Lung, and Blood Institute (NHLBI)Recruiting
-
Rabin Medical CenterDreaMed DiabetesTerminated
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States